Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 3/20 | 0.32 |
| ▸ | MAOB | P27338 | 2/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 2/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | EIF4A1 | P60842 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL610523 | 1.00 | KDM1A (0.32) | KDM1AMAOBMAOAHTR2CADRA1A | |
| SCHEMBL612993 | 0.85 | KDM1A (0.31) | KDM1AMAOBMAOA | |
| SCHEMBL612994 | 0.85 | KDM1A (0.31) | KDM1AMAOBMAOA | |
| SCHEMBL9039255 | 0.78 | KDM1A (0.37) | KDM1AMAOBMAOAHTR2CADRA1A | |
| SCHEMBL9040240 | 0.78 | KDM1A (0.37) | KDM1AMAOBMAOAHTR2CADRA1A | |
| SCHEMBL7439138 | 0.78 | KDM1A (0.36) | KDM1AMAOBMAOAHTR2CADRA1A | |
| SCHEMBL7439134 | 0.78 | KDM1A (0.36) | KDM1AMAOBMAOAHTR2CADRA1A | |
| SCHEMBL611020 | 0.77 | PARP1 (0.33) | KDM1AMAOBMAOAHTR2A | |
| SCHEMBL610459 | 0.77 | PARP1 (0.33) | KDM1AMAOBMAOAHTR2A | |
| SCHEMBL610458 | 0.77 | PARP1 (0.33) | KDM1AMAOBMAOAHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9359303-B2 | Octahydrobenzoisoquinoline modulators of dopamine receptors and uses therefor | PURDUE RESEARCH FOUNDATION (US) | 2016-06-07 | — | — | US | disclosed |
| EP-2421862-B1 | OCTAHYDROBENZOISOQUINOLINE MODULATORS OF DOPAMINE RECEPTORS AND USES THEREFOR | PURDUE RESEARCH FOUNDATION (US) | 2014-06-11 | — | — | EP | disclosed |
| US-20120041018-A1 | OCTAHYDROBENZOISOQUINOLINE MODULATORS OF DOPAMINE RECEPTORS AND USES THEREFOR | PURDUE RESEARCH FOUNDATION (US) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041018-A1 | OCTAHYDROBENZOISOQUINOLINE MODULATORS OF DOPAMINE RECEPTORS AND USES THEREFOR | DBH, SLC6A3, SLC18A2 | KDM1A 3230/4885MAOB 112/4885MAOA 222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.